Krystal Biotech (FRA:4KB) Shiller PE Ratio: (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €293.00
GF Value €284.27
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Krystal Biotech Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Krystal Biotech  (FRA:4KB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Krystal Biotech Shiller PE Ratio Related Terms


Krystal Biotech Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech Shiller PE Ratio Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Krystal Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:4KB vs AXSM, APGE, IONS: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Krystal Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Shiller PE Ratio falls into.


FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Krystal Biotech's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Krystal Biotech's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.554/333.9520*333.9520
=1.554

Current CPI (Jun. 2026) = 333.9520.

Krystal Biotech Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.067 241.428 -0.093
201612 -0.139 241.432 -0.192
201703 -0.108 243.801 -0.148
201706 -0.078 244.955 -0.106
201709 -1.057 246.819 -1.430
201712 -0.114 246.524 -0.154
201803 -0.170 249.554 -0.227
201806 -0.188 251.989 -0.249
201809 -0.223 252.439 -0.295
201812 -0.246 251.233 -0.327
201903 -0.257 254.202 -0.338
201906 -0.327 256.143 -0.426
201909 -0.227 256.759 -0.295
201912 -0.279 256.974 -0.363
202003 -0.281 258.115 -0.364
202006 -0.329 257.797 -0.426
202009 -0.416 260.280 -0.534
202012 -0.436 260.474 -0.559
202103 -0.622 264.877 -0.784
202106 -0.614 271.696 -0.755
202109 -0.595 274.310 -0.724
202112 -0.841 278.802 -1.007
202203 -1.807 287.504 -2.099
202206 -1.041 296.311 -1.173
202209 -1.182 296.808 -1.330
202212 -1.180 296.797 -1.328
202303 -1.644 301.836 -1.819
202306 -1.154 305.109 -1.263
202309 2.614 307.789 2.836
202312 0.284 306.746 0.309
202403 0.028 312.332 0.030
202406 0.492 314.175 0.523
202409 0.820 315.301 0.869
202412 1.452 315.605 1.536
202503 1.110 319.799 1.159
202506 1.118 322.561 1.157
202509 2.266 324.800 2.330
202512 1.452 324.054 1.496
202603 1.583 330.213 1.601
202606 1.554 333.952 1.554

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €293.00 is trading 3.1% above its estimated GF Value™ of €284.27. GuruFocus considers Krystal Biotech to be Fairly Valued.

Key valuation signals for FRA:4KB:

  • Shiller PE Ratio:
  • GF Value™: €284.27 vs. price of €293.00 (3.1% above fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€293.00
Price
€284.27
GF Value